The report provides a detailed analysis essential for establishing a Valdecoxib production plant. It encompasses all critical aspects necessary for Valdecoxib production, including the cost of Valdecoxib production, Valdecoxib plant cost, Valdecoxib production costs, and the overall Valdecoxib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Valdecoxib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Valdecoxib is a medicine used to relieve pain and reduce swelling in people with conditions like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It also helps ease severe menstrual cramps and acute pain after surgeries. It works by blocking a specific enzyme that causes pain and inflammation and causes fewer stomach problems compared to older pain medicines. It starts working quickly and can provide relief for up to 24 hours. It is prescribed for people who suffer from ongoing joint pain and inflammation, helping them to move more comfortably.
However, it should be used carefully because it can increase the risk of heart problems like heart attacks and strokes, especially if taken in high doses or for a long time. It remains an effective option for managing pain and inflammation for many patients under medical supervision.
The market for Valdecoxib is influenced by its utilisation for patients who cannot tolerate other NSAIDs or for whom other options are ineffective. The increasing cases of chronic inflammatory diseases like rheumatoid arthritis and osteoarthritis, an ageing population, and growing awareness of pain management contribute to its market growth. The usage of advanced technology in developing safer formulations, targeted drug delivery, and personalised treatment affects industrial valdecoxib procurement.
Also, strict regulatory policies focused on safety, regarding cardiovascular risks associated with long-term use, influence supply, pricing, and market access. The innovation in drug formulation and exploring new therapeutic applications further impacts sourcing strategies.
Raw Material for Valdecoxib Production
According to the Valdecoxib production plant project report, the key raw materials used in the production of Valdecoxib include Deoxybenzoin-Hydroxylamine-Butyllithium-Chlorosulfuric Acid.
Production Process of Valdecoxib
The extensive Valdecoxib production cost report consists of the following major industrial production process:
- From Deoxybenzoin: The synthesis of Valdecoxib involves several steps. First, deoxybenzoin is converted into the corresponding oxime by treatment with hydroxylamine under basic conditions. Then, the oxime is treated with two equivalents of butyllithium in tetrahydrofuran (THF) under nitrogen. This is followed by cyclisation in ethyl acetate or acetic anhydride to form the isoxazoline derivative. Finally, the isoxazoline is treated with cold chlorosulfuric acid, and the resulting intermediate is reacted with aqueous ammonia to yield Valdecoxib as the final product.
Valdecoxib has the molecular formula C16H14N2O3S and a molecular weight of 314.4 g/mol. It appears as a white solid with no distinctive odour. It has one hydrogen bond donor and multiple rotatable bonds, contributing to its moderate flexibility. It has a partition coefficient (XLogP) of around 2.6 to 3.15, making it moderately lipophilic. Its topological polar surface area is around 94.57 Ų, reflecting its polar character. It reaches peak plasma concentration approximately three hours after administration, and its half-life ranges from 8 to 11 hours. It binds strongly to plasma proteins (about 98%) and shows good oral bioavailability (around 83%). All these physical and chemical properties make it useful as an anti-inflammatory, analgesic, and antipyretic agent in pharmacological applications.